Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday.

Commonwealth Bank of Australia (CBA) reported a 6% rise in third-quarter cash earnings on Wednesday, helped by growth in ...

Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs ... Management forecasts $2.3–$2.4 billion in revenue for 2025, implying nearly 60% growth at the midpoint, driven in ...

Investors and analysts had expected it to work at least as well as Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S ... s US-listed shares fell 8.4% following Lilly’s data.

Investors and analysts had expected it to work at least as well as Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S ... s U.S.-listed shares fell 8.4% following Lilly’s data.

Yahoo Finance has all the latest market moving Merger & IPO news and analysis to help you stay up to date and make informed ...

“Because the US is trying to shift from imported to domestic sources, you might get US demand falling,” Amar Breckenridge, senior associate at Frontier ... maker Novo Nordisk and German ...

Story May 8 - Korro Bio: The Novo Nordisk-partnered ... told Fierce Biotech. Frontier declined to share what percentage of its workforce would be impacted. Story Feb. 4 - Kyowa Kirin: The Japanese ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...